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The fragile histidine triad (FHIT) gene, encompassing the FRA3B fragile site at chromosome 3p14.2, is a candidate tumour suppressor
gene involved in a variety of tumours, including gastric carcinomas. Recently, it has been reported that the FHIT gene may be a target
of damage in some of mismatch-deficient tumours. To clarify further the role of the Fhit protein in gastric carcinogenesis, we
investigated whether Fhit expression in early gastric neoplasia is associated with mismatch repair protein expression and cellular
phenotype. Fhit, Mlh1 and phenotypic expression were evaluated immunohistochemically in 87 early gastric neoplasias, comprising 32
adenomas and 55 intramucosal carcinomas, resected by endoscopic mucosal resection therapy. Significant loss or reduction of Fhit
expression was noted in four (12.5%) of the 32 adenomas and 21 (38.2%) of the 55 intramucosal carcinomas. The rate of abnormal
Fhit expression was significantly higher in intramucosal carcinomas than in adenomas (P¼0.021). Moreover, reduced Fhit expression
was found to be significantly associated with loss of Mlh1 expression in early gastric neoplasia (P¼0.0011). Furthermore, we also
detected a significant association between reduced Fhit expression and gastric phenotype (P¼0.0018). These results suggested that
reduced Fhit expression occurs in the early stage of gastric carcinogenesis and could be correlated with a lack of Mlh1 expression and
gastric phenotype.
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A candidate tumour suppressor gene, fragile histidine triad
(FHIT), was identified at chromosome 3p14.2 spanning the FRA3B
common fragile site (Ohta et al, 1996). Abnormal transcripts were
frequently observed in a variety of human cancers including those
of the digestive tract, lung, breast and head and neck (Ohta et al,
1996; Croce et al, 1999). The majority of these abnormalities
include aberrant mRNA transcripts, with the absence of one or
more exons within the mRNA. Genomic analysis demonstrated
frequent allelic loss and homozygous deletions (Ohta et al, 1996;
Croce et al, 1999).
In gastric carcinomas, alterations at the FHIT locus or reduced
expressions of Fhit have been associated with gastric tumour
progression and poor survival of cancer patients (Baffa et al, 1998;
Capuzzi et al, 2000). However, conflicting results from reverse
transcription (RT)–PCR analysis and genomic analysis have been
reported (Ohta et al, 1996; Gemma et al, 1997; Tamura et al, 1997).
In general, in tumours (lung and oesophagus) associated with
environmental carcinogens, alterations in the FHIT gene occur
early in cancer development, but are thought to be a late event in
other cancers and possibly associated with cancer progression to
more aggressive neoplasia (Croce et al, 1999; Kitamura et al, 2001).
Moreover, little is known about Fhit expression in early gastric
neoplasia.
Microsatellite instability (MSI) due to defects in mismatch
repair (MMR) genes such as MLH1 and MSH2 are involved in the
carcinogenesis and tumour progression of sporadic and inherited
human cancers (Eshleman and Makowitz, 1996; Kinzler and
Vogelstein, 1996). Microsatellite instability is reportedly present
in 15–33% of solitary gastric cancers, although mutations of the
MLH1 or MSH2 genes are rare in sporadic gastric cancers (Chong
et al, 1994; Mironov et al, 1994; Strickler et al, 1994; Tamura et al,
1996). Mismatch repair deficiency leads to the accumulation of
base-base mismatches and short insertion/deletion mispairs,
generated as a consequence of DNA replication errors and
homologous recombinations (Eshleman and Makowitz, 1996;
Kinzler and Vogelstein, 1996). Most sporadic gastric cancers with
MSI have been demonstrated to be caused by somatic hyper-
methylation of the MLH1 promoter region, resulting in the
downregulation of MLH1 gene expression (Fleisher et al, 1999,
2001; Kang et al, 1999; Leung et al, 1999; Suzuki et al, 1999). Recent
studies have revealed that immunohistochemistry is a reliable
screening technique for identifying MMR-deficient tumours
(Thibodeau et al, 1996; Marcus et al, 1999).
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benzylamine exposure caused a spectrum of visceral and skin
tumours similar to Muir–Torre syndrome, caused by deficiency in
an MMR gene, in Fhit-deficient mice, and suggested that the FHIT
gene may be a target of damage in some of MMR-deficient
tumours. Moreover, Mori et al (2001) and Andachi et al (2002)
reported that loss of the MMR protein is significantly correlated
with the loss of Fhit expression in human colorectal carcinomas.
While an association between MSI and FHIT alterations has been
reported by Huiping et al (2002), the relationship between Fhit and
Mlh1 expression has not been previously studied in gastric
carcinomas.
Gastric carcinomas have been divided into two histological
types: intestinal and diffuse types, according to Lauren (1965), or
differentiated and undifferentiated types, according to Nakamura
et al (1968). However, mucin histochemical and immunohisto-
chemical examinations have recently demonstrated that gastric
and intestinal phenotypic cell markers are widely expressed in
gastric carcinomas, irrespective of their histological type (Egashira
et al, 1999; Yoshino et al, 1999; Koseki et al, 2000). Moreover, it
has generally been reported that gastric carcinomas with a
predominantly gastric phenotype have a pronounced tendency
toward invasion, metastasis and poor prognosis compared with
gastric carcinomas that have intestinal phenotypic expression
(Endo et al, 1999; Koseki et al, 1999; Yoshino et al, 1999;
Kabashima et al, 2002; Tajima et al, 2002). Therefore, phenotypic
subclassification should be useful in understanding the biologic
behaviour of carcinomas and selecting a suitable therapeutic
method.
To clarify the role of the FHIT gene in the development of gastric
carcinomas, we compared Fhit expression with Mlh1 and
phenotypic expression in gastric adenomas and intramucosal
carcinomas.
MATERIALS AND METHODS
Patient samples
Tumour specimens were obtained from 87 patients (58 male and
29 female subjects), who had undergone endoscopic mucosal
resection at Tottori University Hospital between 1994 and 2000.
Pathologically, 32 lesions were diagnosed as adenomas and 55
lesions as intramucosal carcinomas (Table 1). Macroscopic and
histological evaluations were made according to the classification
established by the Japanese Research Society for Gastric Cancer
(1993). The macroscopic features were divided into two major
types: elevated, and flat or depressed. The depth of invasion and
histological grade were classified according to the predominant
features. In this study, adenoma and intramucosal carcinoma
correspond to low- or high-grade adenoma/dysplasia and non-
invasive carcinoma or intramucosal carcinoma in the Vienna
classification system, respectively (Schlemper et al, 2000).
Helicobacter pylori infection was evaluated in 20 adenomas and
23 intramucosal carcinomas by histology, rapid urease test,
bacterial culture test and serological test, and was defined by a
positive result in any of these four tests. All these cases were
positive. Pathological diagnoses were verified by two experienced
pathologists (HA and HI). All the cases were analysed anon-
ymously, that is, all the specimens were assigned a new number
without any personal information. Institutional Review Board
approval was obtained.
Immunohistochemical staining
Paraffin-embedded, 4mm-thick sections were immunohistochemi-
cally stained with an anti-Fhit rabbit polyclonal antibody (IBL,
Gunma, Japan; dilution 1:100), an anti-Mlh1 mouse monoclonal
antibody (G168-15, PharMingen, San Diego, CA, USA; dilution
1:50), an anti-human gastric mucin (HGM) mouse monoclonal
antibody (45M1, Novocastra Laboratories, Ltd., Newcastle, UK;
dilution 1:50), an anti-MUC2 mouse monoclonal antibody (Ccp58,
Novocastra, Newcastle, UK; dilution 1:100) and an anti-CD10
mouse monoclonal antibody (56C6, Novocastra, Newcastle, UK;
dilution 1:50) using the avidin–biotin–peroxidase complex
technique.
Immunohistochemical staining was performed as described
below. In brief, after being deparaffinised in xylene and rehydrated
in ethanol, the sections were immersed in a citrate buffer (0.01 M,
pH 6.0) and heated in a microwave oven for 20–30min to retrieve
antigens, then incubated with the primary antibody overnight at
41C. As a negative control, the primary antibody was replaced with
normal serum IgG at a similar dilution. The detection reaction
followed the Vectastain Elite ABC kit protocol (Vector Labora-
tories, Burlingame, CA, USA). Diaminobenzidine was used as a
chromogen, and methylgreen or haematoxylin as a counterstain.
The sections were incubated with biotinylated anti-rabbit or
mouse IgG and avidin–biotin–peroxidase and visualised using
diaminobenzidine tetrahydrochloride.
Then, paradoxical concanavalin A (ConA, Vector Laboratories,
Burlingame, CA, USA) staining was carried out according to the
method of Kabashima et al (2002).
The protein expression was evaluated by two independent
observers (HA and KY). Immunohistochemical analysis was
performed in a blinded manner with respect to the clinical
information.
Assessment of Fhit immunostaining
The Fhit expression was graded for both the extent and intensity of
immunopositivity, as described previously (Hao et al, 2000). The
extent of positivity was scored as follows: 0,o5%; 1, 5–25%; 2,
25–50%; 3, 50–75% and 4, 475% of the gastric epithelial cells in
the respective lesions. The intensity was scored as follows: 0,
negative; 1þ, weak; 2þ, moderate and 3þ, as strong as normal
mucosa. The final score was obtained by multiplying the positivity
and intensity scores, producing a range from 0 to 12. Scores 9–12
were defined as a preserved or strong staining pattern, scores 5–8
were defined as an intermediate staining pattern and scores 0–4
were defined as markedly reduced or lost expression.
Assessment of Mlh1 immunostaining
Normal tissue adjacent to the tumour was used as an internal
positive control. The normal staining pattern for Mlh1 was nuclear.
Tumour cells that exhibited an absence of nuclear staining in the
Table 1 Clinicopathological features in early gastric neoplasia
Adenoma (n¼32)
Intramucosal
carcinoma (n¼55)
Gender (M:F) 18:14 40:15
Age (mean7s.d; years) 71.376.7 70.078.5
Histologic type Mild 2 Tub1 41
(grade) Moderate 20 Tub2 12
Severe 10 Pap 2
Location
Upper 2 4
Middle 15 20
Lower 15 31
Gross classification
Elevated 22 35
Flat or depressed 10 20
Tub1¼well-differentiated tubular adenocarcinoma; Tub2¼moderately differen-
tiated tubular adenocarcinoma; Pap¼papillary adenocarcinoma.
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considered to have an abnormal pattern. Cases with definite
nuclear staining in more than 30% of the tumour cells were
categorised as positive, cases with definite nuclear staining in less
than 30% of the tumour cells were categorised as negative (Beak
et al, 2001).
Assessment of HGM, ConA, MUC2 and CD10
immunostaining and classification of the phenotypes
Human gastric mucin staining was seen in the cytoplasm of the
gastric foveolar epithelium and mucous neck cells, while ConA
staining was seen in the cytoplasm of the pyloric glands. MUC2
staining was seen in the cytoplasm around the nuclei of goblet
cells. CD10 staining was seen along the brush border of the luminal
surface of the epithelium. Although CD10 can also be expressed in
the apical portion of the cytoplasm of normal gastric mucosa, only
the expression of CD10 on the brush border was studied. The
results of staining were categorised into two groups: positive
expression and negative expression. Staining of 410% of the
adenoma and carcinoma cells was classified as positive expression
and o10% was classified as negative expression. The phenotypes
were classified into four categories according to the combination
of the expression of CD10, MUC2, ConA and HGM (Yoshino et al,
1999). The intestinal phenotype (I-type) demonstrated positive
expression for MUC2 and/or CD10, but negative expression for
both HGM and ConA. The gastric and intestinal mixed phenotype
(GI-type) demonstrated positive expression for MUC2 and/or
CD10, and positive expression for HGM and/or ConA. The gastric
phenotype (G-type) demonstrated positive expression for HGM
and/or ConA, but negative expression for both MUC2 and CD10.
The unclassified phenotype (UC-type) demonstrated negative
expression for MUC2, CD10, ConA and HGM.
Statistical analysis
Statistical analysis was performed by the w
2 test or Fischer’s exact
test (two-sided). Po0.05 was considered significant.
RESULTS
Fhit expression in the normal epithelium and neoplasia of
the stomach
Normal gastric epithelia adjacent to the tumour cells showed
moderate to strong cytoplasmic expression of the Fhit protein
from the basal portion to the luminal differentiated cells; these
findings served as internal positive controls. Smooth muscle cells
and inflammatory mononuclear cells were positive at various
intensities and degrees. Reduced or absent staining for Fhit was
recognised in four (12.5%) of the 32 adenomas and in 21 (38.2%)
of the 55 intramucosal carcinomas (Figure 1A and B, Table 2). The
incidence of reduced Fhit expression was significantly higher in
the intramucosal carcinomas than in the adenomas (P¼0.021).
However, no significant associations were found among Fhit
expression and other clinicopathological parameters (data not
shown).
Mlh1 expression in the normal epithelium and neoplasia of
the stomach
The expression of Mlh1 protein was observed exclusively in the
nucleus. In normal tissue adjacent to the tumour cells, Mlh1
expression was detected predominantly in the proliferative zone,
such as the germinal centres of lymphoid follicles and normal
glands. Normal stromal cells such as fibroblasts and endothelial
cells also showed nuclear positivity for this protein. Loss of Mlh1
expression was detected in one (3.1%) of the 32 adenomas and 14
(25.5%) of the 55 intramucosal carcinomas (Figure 2A and B,
Table 2). The incidence of Mlh1 expression loss was significantly
higher in the intramucosal carcinomas than in the adenomas
Figure 1 Fhit immunostaining in human gastric non-neoplastic and
neoplastic tissues. (A) Negative immunostaining of an intramucosal
carcinoma and positive immunostaining of a non-neoplastic epithelium.
(B) Positive immunostaining of an adenomatous and non-neoplastic
epithelium.
Table 2 Immunohistological findings in early gastric neoplasia
Adenoma (n = 32)
Intramucosal
carcinoma (n = 55)
Fhit expression
Preserved or intermediate 28 34
Reduced or absent 4
a
 21
Mlh1 expression
+3 1 4 1
 1
b
14
Phenotype
G-type 2 c 16
GI-type 10 18
I-type 20 d 19
UC-type 0 2
−
aP¼0.021, rate of abnormal Fhit expression in adenoma is lower than that in
carcinoma.
bP¼0.0076, rate of abnormal Mlh1 expression in adenoma is lower than
that in carcinoma.
cP¼0.013, rate of G-type in adenoma is lower than that in
carcinoma.
dP¼0.011, rate of I-type in adenoma is higher than that in carcinoma.
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clinicopathological parameters (data not shown).
Distribution of the phenotype in early gastric neoplasia
The distributions of phenotype in the adenomas and intramucosal
carcinomas were two (6.3%) of 32 and 16 (29.1%) of 55 for the G-
type, 10 (31.3%) of 32 and 18 (32.7%) of 55 for the GI-type, and 20
(62.5%) of 32 and 20 (36.4%) of 55 for the I-type, respectively. The
frequency of the G-type in carcinomas (P¼0.013) and the I-type in
adenomas (P¼0.011) was significantly higher than in the others
(Table 2).
Correlation of Fhit expression with Mlh1 expression in
early gastric neoplasia
Among the early neoplasias with reduced or absent Fhit
expression, 10 (40.0%) of 25 showed a loss of nuclear Mlh1
expression, in contrast to five (8.1%) of 62 neoplasias with
preserved or intermediate Fhit expression (P¼0.0011) (Table 3).
Regarding intramucosal carcinomas, 42.9% (nine of 21) of the
reduced or absent Fhit expression carcinomas were negative for
Mlh1 expression, whereas 14.7% (five of 34) of the preserved or
intermediate Fhit expression carcinomas were Mlh1 negative
(P¼0.044). In the adenomas, the one case with Mlh1-negative
expression was one of the four-Fhit-reduced samples.
Relationship between phenotype and expression of Fhit
and Mlh1 protein in early gastric neoplasia
Decreased or nonstaining for Fhit was detected in 11 (61.1%) of 18
G-type, eight (28.6%) of 28 GI-type and five (12.8%) of 39 I-type
early gastric neoplasia (Table 4). The incidence of reduced
Fhit expression in early gastric neoplasia was significantly
more frequent in the G-type compared with the others
(P¼0.0018). Regarding intramucosal carcinomas, 52.4%
(11 of 21) of the reduced or absent Fhit expression carcinomas
were G-type, whereas 14.7 % (five of 34) of the preserved or
intermediate Fhit expression carcinomas were G-type (P¼0.0073).
Loss of Mlh1 expression was detected in eight (44.4%) of 18 G-
type, four (14.3%) of 28 GI-type and two (5.1%) of 39 I-type
(Table 4). The incidence of Mlh1 expression loss in early gastric
neoplasia was significantly higher in the G-type than in the others
(P¼0.0021).
DISCUSSION
Alterations and abnormal transcripts of the FHIT gene have been
reported in a number of primary human tumours, including
gastric carcinoma (Ohta et al, 1996; Croce et al, 1999). However,
some of the data regarding gastric carcinoma are conflicting (Ohta
et al, 1996; Gemma et al, 1997; Tamura et al, 1997). It was reported
that alterations in the FHIT locus detected by DNA and/or RT–
PCR analysis closely correlated with a loss of Fhit protein
expression in lung and gastric carcinomas (Baffa et al, 1998; Sozzi
et al, 1998). These results indicated that FHIT gene alteration could
be detected simply by immunohistochemical analysis of tumour
specimens. In this study, we observed abnormal Fhit protein
expression in intramucosal carcinomas, with 38.2% of specimens
demonstrating a decrease in, or absence of, Fhit protein staining.
Figure 2 Mlh1 immunostaining in human gastric non-neoplastic and
neoplastic tissues. (A) Negative immunostaining of an intramucosal
carcinoma and positive immunostaining of a non-neoplastic epithelium.
(B) Positive immunostaining of an intramucosal carcinoma and non-
neoplastic epithelium.
Table 3 Relationship between Fhit and Mlh1 expression in early gastric
neoplasia
Fhit expression
Mlh1expression No.
Preserved or
intermediate
Reduced or
absent
+7 2 5 7 1 5
  15 5 10
P¼0.0011, reduced or absent expression of Fhit is associated with loss of Mlh1.
Table 4 Relationship between phenotype and Fhit and Mlh1 expression
in early gastric neoplasia
Fhit Mlh1
Phenotype No.
Preserved or
intermediate
Reduced or
absent +  
G-type 18 7 11 10 8
GI-type 28 20 8 24 4
I-type 39 34 5 37 2
UC-type 2 1 1 1 1
Total 87 62 25 72 15
_
ed
eP¼0.0018, rate of abnormal Fhit expression in the G-type is higher than that in the
others.
dP¼0.002, rate of abnormal Mlh1 expression in the G-type is higher than that
in the others.
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compared with that observed in advanced gastric carcinomas in
previous reports (Baffa et al, 1998; Capuzzi et al, 2000). Therefore,
abnormal Fhit expression may be associated with tumour
progression in gastric carcinomas. However, we found no
correlation between Fhit expression and any of the clincopatho-
logical parameters.
Alterations in the FHIT gene and its expression have been
reported even in premalignant lesions of the lung, colon and
oesophagus (Sozzi et al, 1998; Croce et al, 1999; Kitamura et al,
2001). We found a significantly reduced Fhit expression in 12.5%
of gastric adenomas. However, there was no correlation between
Fhit expression and the severity of histopathological changes.
Caselli et al (2001) reported that reduced Fhit expression was not
detected in precancerous lesions of the stomach. Another recent
study on early gastric neoplasia revealed a higher frequency of
abnormal Fhit expression comparable to studies on advanced
gastric cancer (Skopelitou et al, 2003). These discrepancies may be
caused by differences in immunohistochemical techniques, the
anti-FHIT antibody used, interpretation of immunoreactivity,
sample number, sample type or different distributions of
histological grade. Moreover, we found that the rate of reduced
Fhit expression was significantly lower in gastric adenomas than
that in intramucosal carcinomas. These results suggest that Fhit
protein may have a functional role in the early stage of gastric
tumorigenesis.
Inactivation of MMR genes has been described as an
alternative pathway in cancer development and progression
(Eshleman and Makowitz, 1996; Kinzler and Vogelstein, 1996).
Microsatellite instability is found in 15–33% of sporadic gastric
cancers, a higher incidence than that seen in other types of
sporadic human cancers (Chong et al, 1994; Mironov et al, 1994;
Strickler et al, 1994; Tamura et al, 1996). Recent studies have
suggested that silencing of the MLH1 gene by promoter
hypermethylation is a major causative event in the development
of human gastric cancers with MSI (Fleisher et al, 1999, 2001;
Kang et al, 1999; Leung et al, 1999; Suzuki et al, 1999). The
majority of these tumours also exhibited loss of Mlh1 protein
expression. Thus, our finding of loss of Mlh1 expression in 14
(25.5%) of the 55 intramucosal carcinomas coincides with
published frequencies. However, only one (3.1%) of the 32
adenomas showed Mlh1 expression loss. This abnormal Mlh1
protein expression was less frequent than that observed in gastric
adenomas reported by other investigators (Beak et al, 2001). This
might be partly due to different diagnostic criteria for gastric
adenoma, different criteria for the loss of Mlh1 expression, varying
degrees of dysplasia and the limited number of tested cases.
Moreover, we indicated that the rate of reduced Mlh1 expression in
gastric adenomas was significantly lower than that in intramucosal
carcinomas, which is consistent with a previous report (Beak et al,
2001).
Recently, it has been reported that following N-nitrosomethyl-
benzylamine exposure, Fhit-deficient mice developed a spectrum
of visceral and skin tumours similar to Muir–Torre syndrome,
caused by deficiency in an MMR gene (Fong et al, 2000). A large
subgroup of Muir–Torre syndrome cases exhibits MSI and
germline mutations in the MLH1 or MSH2 gene (Kruse et al,
1998). In addition, it was previously observed that frequent human
pancreatic cancers and cell lines with high MSI had homozygous
deletions within FHIT (Hilgers and Kern, 1999; Hilgers et al, 2000).
Therefore, these reports suggest that the FHIT gene might be a
target of damage in some MMR-deficient tumours. Our data show
that MMR deficiency based on the status of Mlh1 protein
expression is significantly associated with reduced Fhit expression
in early gastric neoplasias, supporting this hypothesis. Mori
et al (2001) and Andachi et al (2002) reported an association
between MMR deficiency and FHIT alterations in colorectal
carcinomas. Moreover, as a mechanism for this, they proposed
that repetitive elements, such as (CA)n and (A)n repeats, in introns
4 and 5 of the FHIT gene could be a target of damage in MMR-
deficient tumours.
It has been reported that there are obvious differences in the
biological behaviour of gastric phenotype carcinomas and
intestinal phenotype carcinomas (Egashira et al, 1999; Yoshino
et al, 1999; Koseki et al, 2000). Generally, gastric phenotype
carcinomas are considered to have greater invasiveness and
metastatic potential than intestinal phenotype carcinomas (Endo
et al, 1999; Koseki et al, 1999; Yoshino et al, 1999; Kabashima et al,
2002; Tajima et al, 2002). In this study, the incidence of reduced or
lost Fhit expression in G-type early gastric neoplasias (61.1%) was
significantly higher than that in GI-type (28.6%) or I-type (12.8%)
early gastric neoplasias. Capuzzi et al (2000) reported that the
absence of Fhit protein correlated with the progression of gastric
carcinomas, higher histological grade and poorer prognosis.
Furthermore, MMR-deficient mouse cell lines show increased
chromosome fragility (Turner et al, 2002). Therefore, combined
analyses of phenotypic expression and Fhit expression by
immunohistochemistry could be useful methods for evaluating
the malignant potential of gastric neoplasias. In addition, gastric
phenotype tumours were associated with a loss of Mlh1 expression.
In terms of the relationship between genetic alterations and
phenotypes of differentiated-type carcinomas, Endo et al (1999)
reported that MSI was detected more frequently in gastric
phenotype carcinomas than in intestinal phenotype carcinomas,
which is consistent with the present results. Furthermore, we
indicated that the incidence of gastric phenotype in gastric
adenomas was significantly lower than that in intramucosal
carcinomas. This result was also consistent with a previous report
(Tsukashita et al, 2001).
In conclusion, we demonstrated reduced Fhit expression in
early-stage gastric tumorigenesis, and showed that it was
associated with a loss of Mlh1 protein expression and gastric
phenotype. Studies that explore the correlation between particular
molecular mechanisms and phenotypic expression in neoplasias
may offer new insight into gastric carcinogenesis, cancer treatment
and feasible chemopreventive pathways.
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